Business Description
Senores Pharmaceuticals Ltd
ISIN : INE0RB801010
Total Employee Number:
194Compare
Compare
Traded in other countries / regions
SENORES.India IPO Date
2024-12-30Description
Senores Pharmaceuticals Ltd is a research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the Regulated Markets of the USA, Canada and United Kingdom across various therapeutic areas and dosage forms, with a presence in Emerging Markets. Its strength lies in identifying, developing and manufacturing a diverse range of specialty, underpenetrated and complex pharmaceutical products establishing the company as a preferred partner to certain customers. Through data analytics, research, market assessment and experienced management, It strategically identifies commercially underpenetrated molecules to launch products in the Regulated and Emerging Markets.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.97 | |||||
Equity-to-Asset | 0.58 | |||||
Debt-to-Equity | 0.37 | |||||
Debt-to-EBITDA | 1.59 | |||||
Interest Coverage | 6.15 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 7.19 | |||||
Beneish M-Score | -1.77 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 166.2 | |||||
3-Year EBITDA Growth Rate | 141.8 | |||||
3-Year EPS without NRI Growth Rate | 143.3 | |||||
3-Year FCF Growth Rate | -64.1 | |||||
3-Year Book Growth Rate | 173.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 40.95 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 40.51 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 79.6 | |||||
9-Day RSI | 75.99 | |||||
14-Day RSI | 73.31 | |||||
3-1 Month Momentum % | 35.45 | |||||
6-1 Month Momentum % | 37.12 | |||||
12-1 Month Momentum % | 89.22 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.92 | |||||
Quick Ratio | 1.71 | |||||
Cash Ratio | 0.78 | |||||
Days Inventory | 100.81 | |||||
Days Sales Outstanding | 126.45 | |||||
Days Payable | 205.81 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shareholder Yield % | -0.46 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 59.65 | |||||
Operating Margin % | 24.68 | |||||
Net Margin % | 18.5 | |||||
EBITDA Margin % | 34.53 | |||||
FCF Margin % | -32.5 | |||||
OCF Margin % | 9.95 | |||||
ROE % | 13.66 | |||||
ROA % | 8.4 | |||||
ROIC % | 13.87 | |||||
3-Year ROIIC % | 10.77 | |||||
ROC (Joel Greenblatt) % | 42.44 | |||||
ROCE % | 17.39 | |||||
Years of Profitability over Past 10-Year | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 53.72 | |||||
Forward PE Ratio | 43.46 | |||||
PE Ratio without NRI | 53.72 | |||||
PS Ratio | 9.89 | |||||
PB Ratio | 6.99 | |||||
Price-to-Tangible-Book | 11.91 | |||||
Price-to-Operating-Cash-Flow | 99.9 | |||||
EV-to-EBIT | 35.68 | |||||
EV-to-EBITDA | 30.5 | |||||
EV-to-Revenue | 10.53 | |||||
EV-to-FCF | -32.42 | |||||
Price-to-Graham-Number | 5.33 | |||||
| Price-to-Net-Current-Asset-Value | 45.91 | |||||
Earnings Yield (Greenblatt) % | 2.8 | |||||
FCF Yield % | -3.1 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Senores Pharmaceuticals Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 6,237 | ||
| EPS (TTM) (₹) | 26.39 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 35.55 | ||
| 14-Day RSI | 73.31 | ||
| 14-Day ATR (₹) | 58.338577 | ||
| 20-Day SMA (₹) | 1324.37 | ||
| 12-1 Month Momentum % | 89.22 | ||
| 52-Week Range (₹) | 585.9 - 1487.9 | ||
| Shares Outstanding (Mil) | 46.05 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Senores Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Senores Pharmaceuticals Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Senores Pharmaceuticals Ltd Frequently Asked Questions
What is Senores Pharmaceuticals Ltd(NSE:SENORES)'s stock price today?
The current price of NSE:SENORES is ₹1417.80. The 52 week high of NSE:SENORES is ₹1487.90 and 52 week low is ₹585.90.
When is next earnings date of Senores Pharmaceuticals Ltd(NSE:SENORES)?
The next earnings date of Senores Pharmaceuticals Ltd(NSE:SENORES) is .
Does Senores Pharmaceuticals Ltd(NSE:SENORES) pay dividends? If so, how much?
Senores Pharmaceuticals Ltd(NSE:SENORES) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Senores Pharmaceuticals Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers